Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

RNAi Screening Uncovers a Synthetic Sick Interaction between CtIP and the BARD1 Tumor Suppressor.

Cells | 2022

Human CtIP is best known for its role in DNA end resection to initiate DNA double-strand break repair by homologous recombination. Recently, CtIP has also been shown to protect reversed replication forks from nucleolytic degradation upon DNA replication stress. However, still little is known about the DNA damage response (DDR) networks that preserve genome integrity and sustain cell survival in the context of CtIP insufficiency. Here, to reveal such potential buffering relationships, we screened a DDR siRNA library in CtIP-deficient cells to identify candidate genes that induce synthetic sickness/lethality (SSL). Our analyses unveil a negative genetic interaction between CtIP and BARD1, the heterodimeric binding partner of BRCA1. We found that simultaneous disruption of CtIP and BARD1 triggers enhanced apoptosis due to persistent replication stress-induced DNA lesions giving rise to chromosomal abnormalities. Moreover, we observed that the genetic interaction between CtIP and BARD1 occurs independently of the BRCA1-BARD1 complex formation and might be, therefore, therapeutical relevant for the treatment of BRCA-defective tumors.

Pubmed ID: 35203293 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: Swiss National Science Foundation, Switzerland
    Id: 31003A_156023
  • Agency: Swiss National Science Foundation, Switzerland
    Id: 31003A_176161
  • Agency: Swiss Cancer Research Foundation,
    Id: KFS-3025-08-2012
  • Agency: Swiss Cancer Research Foundation,
    Id: KFS-3845-02-2016
  • Agency: Swiss Cancer Research Foundation,
    Id: KFS-4702-02-2019
  • Agency: Promedica Stiftung,
    Id: (1317/M)
  • Agency: Swiss National Science Foundation, Switzerland
    Id: PP00P3_179057
  • Agency: Swiss National Science Foundation, Switzerland
    Id: 310030_197003
  • Agency: European Research Council, International
    Id: ERC-2016-STG 714326
  • Agency: LENDULET-BIOMAG,
    Id: 2018-342
  • Agency: European Regional Development Funds,
    Id: GINOP-2.3.2-15-2016-00001

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


U2OS (tool)

RRID:CVCL_0042

Cell line U2OS is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HEK293 (tool)

RRID:CVCL_0045

Cell line HEK293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HEK293T (tool)

RRID:CVCL_0063

Cell line HEK293T is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Flp-In-T-REx-293 (tool)

RRID:CVCL_U427

Cell line Flp-In-T-REx-293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions